Literature DB >> 12145236

Using HbA(1c) to improve efficacy of the american diabetes association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study.

Wenyu Wang1, Elisa T Lee, Richard Fabsitz, Thomas K Welty, Barbara V Howard.   

Abstract

OBJECTIVE: To find an optimal critical line in the fasting plasma glucose (FPG)-HbA(1c) plane for identifying diabetes in participants with impaired fasting glucose (IFG) and thereby improve the efficacy of using FPG alone in diabetes screening among American Indians. RESEARCH DESIGN AND METHODS: We used FPG, 2-h postload glucose (2hPG), and HbA(1c) measured in the 2,389 American Indians (aged 45-74 years, without diabetes treatment or prior history of diabetes) in the Strong Heart Study (SHS) baseline (second) examination. Participants were classified as having diabetes if they had either FPG > or =126 mg/dl or 2hPG > or =200 mg/dl, as having IFG if they had 110 < or = FPG < 126 mg/dl, and as having normal fasting glucose (NFG) if they had FPG <110, according to the American Diabetes Association (ADA) definition. Logistic regression models were used for identifying diabetes (2hPG > or =200 mg/dl) in IFG participants. The areas under the receiver operating characteristic (ROC) curves generated by different logistic regression models were evaluated and compared to select the best model. A utility function based on the best model and the cost-to-benefit ratio was used to find the optimal critical line. The data from the second examination were used to study the effect of the time interval between the successive diabetes screenings on both the FPG criterion and the optimal critical line.
RESULTS: A total of 37% of all subjects with new diabetes at baseline and 55.2% of those in the second exam had 2hPG > or =200 but FPG <126. There was a very large portion of IFG participants with diabetes (19.3 and 22.9% in the baseline and second exam, respectively). Among the areas under the ROC curves, the area generated by the logistic regression model on FPG plus HbA(1c) is the largest and is significantly larger than that based on FPG (P = 0.0008). For a cost-to-benefit ratio of 0.23888, the optimal critical line that has the highest utility is: 0.89 x HbA(1c) + 0.11 x FPG = 17.92. Those IFG participants whose FPG and HbA(1c) were above or on the line were referred to take an oral glucose tolerance test (OGTT) to diagnose diabetes. The optimal critical line is lower if a successive diabetes screening will be conducted 4 years after the previous screening.
CONCLUSIONS: FPG > or =126 and 2hPG > or =200, as suggested by the ADA, are used independently to define diabetes. The FPG level is easy to obtain, and using FPG alone is suggested for diabetes screening. It is difficult to get physicians and patients to perform an OGTT to get a 2hPG level because of the many drawbacks of the OGTT, especially in those patients who already have FPG <126. It is also impractical to conduct an OGTT for everyone in a diabetes screening. Our data show that 37% of all subjects with new diabetes in the SHS baseline exam and 55.2% of those in the second exam have 2hPG > or =200 but FPG <126. These cases of diabetes cannot be detected if FPG is used alone in a diabetes screening. Therefore, although the small portion of diabetes in the NFG group (4.7% in the baseline and 6.9% in the second exam) may be ignored, those cases of diabetes among IFG participants ( approximately 20% in our data) need further consideration in a diabetes screening. It may be worthwhile for those IFG participants identified by the optimal critical line to take an OGTT. The optimal critical line and time interval between successive diabetes screenings need further study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145236     DOI: 10.2337/diacare.25.8.1365

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  HbA(1c) values for defining diabetes and impaired fasting glucose in Asian Indians.

Authors:  Manisha Nair; Dorairaj Prabhakaran; K M Venkat Narayan; Rashmi Sinha; Ramakrishnan Lakshmy; Niveditha Devasenapathy; Carrie R Daniel; Ruby Gupta; Preethi S George; Aleyamma Mathew; Nikhil Tandon; K Srinath Reddy
Journal:  Prim Care Diabetes       Date:  2011-04-06       Impact factor: 2.459

2.  Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study.

Authors:  Wenyu Wang; Elisa T Lee; Barbara V Howard; Richard R Fabsitz; Richard B Devereux; Thomas K Welty
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

3.  A two-step screening, measurement of HbA1c in association with FPG, may be useful in predicting diabetes.

Authors:  Kyoko Nomura; Kazuo Inoue; Kimihiko Akimoto
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

4.  Is it time to take a different approach to screening people at high risk for type 1 diabetes?

Authors:  Edward J Boyko; Jerry P Palmer
Journal:  Diabetes Care       Date:  2009-05       Impact factor: 19.112

5.  Does homeostasis model assessment of insulin resistance have a predictive value for post-coronary artery bypass grafting surgery outcomes?

Authors:  Ebuzer Aydin; Mehmet Ozkokeli
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep

6.  Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study.

Authors:  Jorge R Kizer; Jason G Umans; Jianhui Zhu; Richard B Devereux; Robert L Wolfert; Elisa T Lee; Barbara V Howard
Journal:  Diabetes Care       Date:  2012-02-14       Impact factor: 19.112

7.  Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects.

Authors:  Zilin Sun; Jiajia He; Shanhu Qiu; Chenghao Lei; Yi Zhou; Zuolin Xie; Lin Zhang; Yanping Wang; Hui Jin
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

8.  Identification of Newly Diagnosed Diabetes and Prediabetes Using Fasting Plasma Glucose and Urinary Glucose in a Chinese Population: A Multicenter Cross-Sectional Study.

Authors:  Juan Chen; Hai Jian Guo; Shan-Hu Qiu; Wei Li; Xiao-Hang Wang; Min Cai; Bei Wang; Xiao-Ning Li; Zi-Lin Sun
Journal:  Chin Med J (Engl)       Date:  2018-07-20       Impact factor: 2.628

9.  Large Cohort Data Based Cost-Effective Disease Prevention Design Strategy: Strong Heart Study.

Authors:  Wenyu Wang; Elisa T Lee; Barbara V Howard; Richard Devereux; Ying Zhang; Julie A Stoner
Journal:  World J Cardiovasc Dis       Date:  2018-12-29

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.